

Press release 2019-08-30

WntResearch increases resources for out-licensing of Foxy-5

WntResearch and The Sage Group have initiated a collaboration to accelerate the process of identifying and engaging potential partners prior to readout of the on-going Phase 2 study with Foxy-5.

Cancer is by far the largest research area in the pharmaceutical industry and the number of companies focusing on developing and commercializing new cancer treatments amounts to several thousands.

In order to increase the visibility of Foxy-5 and engage companies with the right focus and interest in a discussion about a potential future partnership, WntResearch has chosen to start a collaboration with The Sage Group (Sage) based in USA, Europe and Asia. With Sage, WntResearch gains access to one of the market's largest global networks and a partner with repeatedly successful transactions on its' track record. Sage has 25 years of experience supporting innovative research companies in strategy work and business negotiations. Collaboration with Sage involves efforts throughout the process up to the goal of a successful transaction.

“To optimize the business potential for Foxy-5, we need a pharmaceutical company that can take the project all the way to successful commercialization. Through the collaboration with Sage with a strong reputation based on repeated successes in transactions, we gain a clear reinforcement of our ability to reach the right potential partners. We want to start work pro-actively and create a continuous dialogue with a selection of interesting partners, so that we are ready for business discussions in connection with important data read out from our ongoing phase 2 study. Sage will be part of our team and I am looking forward to this collaboration very much,” says WntResearch’s CEO Peter Morsing.

Dr. Bill Mason, Sage Group’s lead partner in Europe, says “We are delighted to work with WntResearch, who in our view are leaders in the field of anti-metastatic therapy. Foxy-5 has performed well in all clinical studies to date, and we believe the drug candidate has enormous potential to succeed in clinical control of cancer. Foxy-5 is likely to be of strong interest to our large network of colleagues in the oncology therapeutics market and we look forward to engaging with them to identify strategic partners for Foxy-5.”

For further information please contact:

Peter Morsing, CEO, WntResearch AB

E-mail: pm@wntresearch.com

Phone: 0727 200711

This information is information that WntResearch AB is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on August 30, 2019.



About WntResearch

WntResearch develops a completely new type of cancer drug that works by inhibiting the ability of tumor cells to spread throughout the body and form metastases. Metastases are the main reason why people die from cancer and treatment to prevent this is missing. Foxy-5, the company's most advanced drug candidate, is a peptide that mimics the body-protein WNT5A. Foxy-5 has been shown in preclinical experimental models to reduce the motility and invasion of tumor cells and thus counteract the onset of metastases. Results from phase 1 studies in patients with colon, prostate or breast cancer show a favourable safety profile and pharmacokinetics as well as early indications of biological activity. Recently, a phase 2 multicenter study in colon cancer patients was started to study the anti-metastatic effect of Foxy-5. WntResearch is listed on the Spotlight Stock Market. For more information visit: www.wntresearch.com

About the Sage-group

The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals have also held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist its clients to migrate their R&D programmes into the clinical and ultimately gain regulatory approval for marketing, by strategic partnering initiatives. For more information visit www.sagehealthcare.com